The Filing Desk

Ardelyx vs Sinovac Biotech

Ardelyx ARDX · Sinovac Biotech SVA · Pharmaceuticals

Ardelyx reported revenue of $407 million in fiscal 2025, about the same as Sinovac Biotech's $386 million in fiscal 2025. Ardelyx's revenue grew 22.1% in its latest year, and Sinovac Biotech's grew 6.8%. Ardelyx had an operating margin of -10.1%, against -127.0% at Sinovac Biotech. Free cash flow was −$44 million at Ardelyx and −$561 million at Sinovac Biotech.

Side by side

ArdelyxSinovac Biotech
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$407M$386M
Revenue growth22.1%6.8%
Revenue growth a year, last 5 years121.7%−5.4%
Gross margin90.3%67.9%
Operating margin−10.1%−127.0%
Net margin−15.1%−51.5%
Free cash flow−$44M−$561M
Free cash flow margin−10.8%−145.4%
Return on capital−36.1%—
Net debt to EBITDA——
Dividends and buybacks$0M$3.5B
Change in diluted share count2.5%0.0%
Last close$3.06—
P/E at the last close——
Insider trades, last 12 monthsbought $1.9 million, sold $4.3 million—
Piotroski F-score2 of 93 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ArdelyxSinovac Biotech
Operating margin
Percent of revenue
ArdelyxSinovac Biotech
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArdelyxSinovac Biotech

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ardelyx and Sinovac Biotech pages.